Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
University of Sydney, Sydney, New South Wales, Australia.
Colorectal Dis. 2018 Apr;20(4):288-295. doi: 10.1111/codi.13951.
In view of the increasing burden on the healthcare system, this study aims to perform a cost-effectiveness analysis of the management of incurable large bowel obstruction comparing the cost of a stent vs surgery.
A prospective randomized controlled trial was conducted at two major teaching hospitals in Australia between September 2006 and November 2011. Fifty-six patients with malignant incurable large bowel obstruction were randomized to stent insertion or surgical decompression, of whom 52 were included in the final analysis. Data were collected at all points during the patient journey and quality of life data were obtained by patient surveys. All data points were analysed and a cost-effectiveness study was performed to compare the costs between the two treatment groups.
Stenting as a procedure was significantly more expensive than surgery (A$4462.50 vs A$3251.50; P < 0.001). Post-procedure stay for stented patients was significantly lower (median 7 vs 11 days; P = 0.03). Combined costs of stent group ward stay, multidisciplinary team discussion and complication management were significantly lower (P = 0.013). Overall cost difference between the two treatment groups was A$3902.44 (P = 0.101). European Quality of Life - 5 Dimensions (EQ-5D) scores for the first 4 weeks gave mean area under the curve adjusted weeks of 2.411 vs 2.271 for the stent and surgery groups respectively (P = 0.603). The incremental cost-effectiveness ratio between the surgery and the stent group was $22 955.53 in favour of stenting.
Treatment with stenting is cheaper than open surgery and provides quicker discharge from hospital.
鉴于医疗系统负担不断增加,本研究旨在对不可治愈性大肠梗阻的管理进行成本效益分析,比较支架与手术的成本。
2006 年 9 月至 2011 年 11 月,在澳大利亚的两家主要教学医院进行了前瞻性随机对照试验。将 56 例恶性不可治愈性大肠梗阻患者随机分为支架置入组或手术减压组,其中 52 例患者纳入最终分析。在患者就诊的各个阶段收集数据,并通过患者调查获得生活质量数据。对所有数据点进行分析,并进行成本效益研究,比较两组治疗的成本。
支架治疗的费用明显高于手术治疗(4462.50 澳元比 3251.50 澳元;P<0.001)。支架治疗患者的术后住院时间明显缩短(中位数 7 天比 11 天;P=0.03)。支架组病房费用、多学科团队讨论和并发症管理的综合成本明显较低(P=0.013)。两组治疗的总费用差异为 3902.44 澳元(P=0.101)。前 4 周欧洲生活质量-5 维(EQ-5D)评分的调整周平均曲线下面积分别为支架组 2.411 和手术组 2.271(P=0.603)。支架组与手术组的增量成本效益比为 22955.53 澳元,支架组更具优势。
支架治疗比开放手术更便宜,并能更快地从医院出院。